NCT02289196View on ClinicalTrials.gov

Safety Study of Vx006 Vaccine in Solid Tumor Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

May 31, 2017

Conditions

Solid Tumor

Interventions

DRUG

Vx-006: 0,5mg

DRUG

Vx-006: 1mg

DRUG

Vx-006: 5mg

DRUG

Vx-006: 10mg

Trial Locations (3)

11525

251 General Airforce Hospital, Athens

15562

Iaso General Hospital, Athens

71110

University General Hospital of Heraklion, Heraklion, Crete

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Vaxon Biotech

INDUSTRY

NCT02289196 - Safety Study of Vx006 Vaccine in Solid Tumor Patients | Biotech Hunter | Biotech Hunter